2 March 2011
PRESS RELEASE:
European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan
Chairman Masuhiro Kato

About Enactment of “JPMA Transparency Guideline”- EFPIA Japan Chairman Statement Today, at the plenary meeting of the Japan Pharmaceutical Manufacturers Association(hereinafter referred to as “JPMA”), the “Guideline for Transparent Relation between
Corporate Activities and Medical Institutions / Healthcare Professionals” (hereinafterreferred to as “Transparency Guideline”) was enacted. In this respect, Masuhiro Kato,
Chairman, European Federation of Pharmaceutical Industries and Associations(hereinafter referred to as “EFPIA”) Japan announced the following comment.

EFPIA Japan has considered since before that it is a social demand to maketransparent the activities of pharmaceutical companies and resolve the issue of benefit
conflict and has deliberated disclosure of information on payments to healthcare
professionals.
For new drug development, the basic researches and the various processes based on
the Pharmaceutical Affairs Law including clinical studies are necessary, and it is said thata long term exceeding 10 years and enormous money reaching 50-100 billion yen arenecessary to develop one new drug. Also after marketing a new drug, it is obligated toinvestigate the use status and report the relevant adverse events as information collection
for promotion of proper use.
As for the expenses necessary for drug creation and promotion of proper use, thepharmaceutical companies are paying adequate considerations to medical institutions and__________________________________________________________________
c/o AstraZeneca K.K.
Marunouchi Trust Tower Main Building, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Tel: +81-3-6301-3066

Fax: +81-3-6268-2861

1healthcare professionals in compliance with the Pharmaceutical Affairs Law, “PromotionCode”, “Fair Competition Code”, etc. after finalizing contracts.
We recognize that it is important to disclose the information on the relation between
pharmaceutical companies and medical institutions or healthcare professionals andincrease the transparency for requesting general citizens to understand that the activities
are conducted under the high ethical standards
Based also on the trend in the Western countries, EFPIA Japan has been engaged inthis issue in collaboration with JPMA. EFPIA Japan welcomes that JPMA enacted thisTransparency Guideline today and would like to promote highly transparent corporate
activities by the member companies according to this Transparency Guideline with theunderstanding of the stakeholders (interested individuals).
In addition, recently, laws to prevent corporate foul actions including Foreign Corrupt
Practices Act in the United States and Bribery Act 2010 in the United Kingdom are newlyenacted. EFPIA Japan would like to make proposals for environmental arrangements sothat corporate activities contributing to the benefit of patients according to the global
standards, i.e., with ethics of the highest level, will be conducted also in Japan.
The end Contact information：
Hideto Kita, Chairman, Public Relations Committee, EFPIA Japan (Public RelationsDepartment, Novartis Pharma)
Phone: 03-3797-8009

2/2